BioCentury
ARTICLE | Clinical News

EyeGate's ocular pain and inflammation candidate misses in Phase IIb

February 9, 2018 6:46 PM UTC

EyeGate Pharmaceuticals Inc. (NASDAQ:EYEG) reported top-line data from a double-blind, U.S. Phase IIb trial to treat post-operative ocular pain and inflammation in 106 patients who had previously undergone cataract surgery with implantation of a monofocal posterior chamber intraocular lens showing that EGP-437 delivered iontophoretically missed the co-primary endpoints vs. placebo. Specifically, EGP-437 failed to significantly improve the proportion of patients with an anterior chamber cell (ACC) count of zero on day seven and the proportion of patients with a pain score of 0 points on day one vs. placebo. EyeGate said the placebo response was "better than anticipated" and that the company will continue to review the data to determine the next steps...

BCIQ Company Profiles

Kiora Pharmaceuticals Inc.